ACS Chemical Biology · 2011 · 114 citations · 25 references
Life SciencesImmunologyOncologyCancer ImmunologyTumor ImmunologyVaccinologyAdjuvant DesignAntigen DesignCancer VaccinesConjugate VaccinesTherapeutic VaccinesTumor-associated AntigensAdjuvant Design For VaccinesAntibodiesCarbohydrate Tumor AntigensCarbohydrate-based AdjuvantsConjugate Vaccine AdjuvantsSynthetic AdjuvantsSynthetic VaccineT-cell Mediated Immunity
Tumor-associated carbohydrate antigens (TACAs) are useful targets in the development of therapeutic cancer vaccines. However, a serious problem with them is the poor immunogenicity. To overcome the problem, a monophosphorylated derivative of Neisseria meningitidis lipid A was explored as a potential carrier molecule and built-in adjuvant for the construction of structurally defined fully synthetic glycoconjugate vaccines. Some paradigm-shifting discoveries about the monophosphoryl lipid A (MPLA)-TACA conjugates were that they elicited robust IgG antibody responses, indicating T cell-mediated immunity, without an external adjuvant and that an external adjuvant, e.g., Titermax Gold, actually reduced rather than promoted the immunological activity of the conjugates. The induced antibodies were proved to bind selectively to target tumor cells. MPLA was therefore demonstrated to be a powerful built-in immunostimulant and adjuvant for an all new design of fully synthetic glycoconjugate cancer vaccines.
25
Subclass Restriction of Murine Anti-Carbohydrate Antibodies
Roger M. Perlmutter, Daniel Hansburg, David E. Briles et al. · The Journal of Immunology · 1978 · 422 citations · Full text
Yoshio Hirabayashi, A Hamaoka, M Matsumoto et al. · Journal of Biological Chemistry · 1985 · 170 citations · Full text
Life Sciences, Immunology, Oncology +17
Therese Buskas, Yanhong Li, Geert‐Jan Boons · Chemistry - A European Journal · 2004 · 170 citations
Gangliosides of Human Melanoma2
Tetsuya Tsuchida, Romaine E. Saxton, Donald L. Morton et al. · JNCI Journal of the National Cancer Institute · 1987 · 163 citations